Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.

The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein.

The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders.

Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp.

The company was founded in 2014 and is headquartered in Boston, Massachusetts.